Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| 5-Amino-1MQ | Humanin | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 50-150 mg daily via oral administration, typically divided into 1-2 doses. | Research indicates dosing remains experimental. Animal studies use 1-10 mcg/day equivalents. Human protocols are not established. |
| Timing | Morning dosing preferred. Can be taken with or without food. | No established timing protocol. Morning dosing suggested for neuroprotective applications. |
| Cycle Duration | 8-12 week cycles. | Experimental — no established cycle lengths. |
| Evidence Level | animal_plus_anecdotal | animal_plus_anecdotal |
5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide, generating 1-methylnicotinamide (1-MNA). By inhibiting NNMT, 5-Amino-1MQ increases intracellular NAD+ levels, reduces 1-MNA production, suppresses lipogenesis in adipocytes, and modulates the methionine-homocysteine cycle. In vivo, it significantly reduces body weight, white adipose mass, and adipocyte size through enhanced energy expenditure and altered lipid metabolism.
Research indicates 50-150 mg daily via oral administration, typically divided into 1-2 doses.
Morning dosing preferred. Can be taken with or without food.
8-12 week cycles.
Humanin is a 24-amino acid mitochondrial-derived peptide encoded by the 16S rRNA gene of mitochondrial DNA. It binds IGFBP-3 with high affinity (via Phe-6), interfering with IGFBP-3 binding to importin-beta and suppressing IGFBP-3-mediated apoptosis. It also inhibits the pro-apoptotic protein Bax (Bcl-2 family), preventing mitochondrial outer membrane permeabilization and intrinsic apoptosis. Humanin and IGFBP-3 synergistically protect neurons from amyloid-beta-induced apoptosis, and it activates the STAT3 and ERK1/2 pathways for cytoprotection.
Research indicates dosing remains experimental. Animal studies use 1-10 mcg/day equivalents. Human protocols are not established.
No established timing protocol. Morning dosing suggested for neuroprotective applications.
Experimental — no established cycle lengths.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →